What the NHS guidelines say about prescribing Mounjaro

What does NICE actually recommend in TA1026?

NICE's appraisal of tirzepatide (published in December 2024 and updated in September 2025) recommends it for adults with a BMI of 35 or above alongside at least one weight-related comorbidity. The qualifying conditions are: type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea, and cardiovascular disease. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, the threshold sits 2.5 kg/m² lower, so 32.5 kg/m² rather than 35.

One detail worth understanding: NICE sets the clinical criteria, but NHS England controls when and how the rollout happens. Those two things move at different speeds. The appraisal is the evidence gate; the commissioning guidance is the access gate.

NICE also specifies that if a patient loses less than five per cent of their body weight after six months at the highest tolerated dose, continuing treatment should be reviewed. The prescriber, not the patient, makes that call. If you want a full breakdown of what the criteria mean in practice, our page covering the NHS guidelines for Mounjaro goes through each requirement in detail so you know exactly where you stand.

What are the current NHS prescribing phases, and who qualifies now?

NHS England has structured the rollout in cohorts to manage demand. The first cohort opened in June 2025: adults with a BMI of 40 or above and four or more of the five qualifying conditions. That is a deliberately narrow group. The second cohort activated on 23 June 2026, widening access to adults with a BMI between 35 and 39.9 alongside four or more conditions.

From around March 2027, the threshold for the number of qualifying conditions drops to three, with BMI remaining at 40 or above. Further phases are planned but not yet confirmed in detail. Ethnic-background adjustments apply at every stage.

It is also worth noting that from 1 April 2026 some GP practices can prescribe under the updated GP contract, but participation is optional. Availability varies significantly by practice and integrated care board area, and if you are based in Scotland you can find out more on our page covering Mounjaro availability through NHS Fife. Meeting the eligibility criteria does not guarantee access; patients must also take part in a structured diet and activity support programme. How NHS prescribing actually works at GP level is covered in more detail for anyone navigating that route.

Does the private route follow the same guidelines?

Private prescribing follows the medicine's licensed criteria rather than the NHS commissioning thresholds. The Mounjaro licence covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as prediabetes, hypertension, high cholesterol or obstructive sleep apnoea. That is a wider group than the current NHS cohorts.

A private prescription still requires a full clinical assessment, a GPhC-registered Independent Prescriber reviews your consultation, medical history and current medications before any decision is made. At nume, that review happens the same day by a named prescriber, not an automated system. Treatment is dispatched once approved, in plain unbranded packaging, delivered free the next working day by DPD.

If you want to understand how private costs compare across providers, our Mounjaro pricing page sets out what a legitimate prescription typically includes and what to check for. And for a broader overview of what Mounjaro is and how it works, the pillar page covers the mechanism, the trial evidence and storage basics, including the kind of detail that matters when you have a pen sitting in the fridge door and want to be sure you're handling it correctly.

What about people who are waiting for the NHS rollout?

A reasonable question. If your BMI and conditions put you in a later cohort, you have a few options: wait for your phase to activate, ask your GP whether your practice has joined the prescribing scheme early, or explore private prescribing through a regulated clinic or pharmacy while you wait.

The NHS England guidance on weight-management injections sets out the wraparound care requirements and what to expect from the NHS pathway. If you are unsure whether you currently qualify under NHS guidelines, your GP is the right first call. For those considering the private route, a separate page works through how NHS and private eligibility differ side by side, which can help you work out the most practical path forward.

Mounjaro is a Black Triangle medicine, meaning it carries additional MHRA monitoring. That does not affect its licensed status, but it is part of why clinical oversight matters on every prescription, NHS or private. If you are ready to see whether private treatment is suitable for you, check your eligibility with our prescribers, there is no charge for the consultation.